Tirzepatide: The First Dual-Action Molecule That Changed Weight Loss Rules

Imagine your body has two "appetite switches," but until now, medications only pressed one. Now there's a molecule that activates both simultaneously. This is exactly how tirzepatide works — and why it showed the best weight loss results in pharmaceutical history.

If you've heard of Ozempic, tirzepatide is the next generation. And the difference isn't cosmetic.

What is tirzepatide and why is the whole world talking about it?

Tirzepatide is the world's first dual GIP and GLP-1 receptor agonist, developed by Eli Lilly [4]. The molecule was approved by the FDA in May 2022 under the brand Mounjaro for treating type 2 diabetes, and in 2023 under the name Zepbound for weight management.

What does this mean in simple terms? Tirzepatide mimics the action of two hormones that your intestine naturally produces after eating. One of them — GLP-1 — you may have heard about in the context of Ozempic. The second — GIP — was never used in any approved product before.

Tirzepatide's molecular structure is similar to semaglutide, but with an important difference: the fatty acid side chain is changed from C18 to C20 diacid, providing week-long action [4]. One injection for 7 days — no daily pills or reminders.

In Ukraine, tirzepatide is available under the brand Mounjaro through the DOZA service. More details about the product can be found on the Mounjaro in Ukraine page.

Dual GIP + GLP-1 mechanism: why "two hands" are better than one?

To understand tirzepatide's uniqueness, we need to understand how these two hormones work.

GLP-1 (glucagon-like peptide-1):

• Stimulates insulin production when blood sugar rises
• Suppresses appetite through satiety centers in the brain
• Slows gastric emptying — you feel full longer [2]

GIP (glucose-dependent insulinotropic polypeptide):

• Enhances insulin secretion together with GLP-1
• Improves insulin sensitivity
• Promotes lipolysis — fat breakdown in fat cells [3]

Semaglutide (Ozempic, Wegovy) activates only the GLP-1 receptor. Tirzepatide activates both — GIP and GLP-1 simultaneously [2].

A detailed comparison with Ozempic will help you understand which option is right for you.

Mounjaro and Zepbound — one tirzepatide, different names

If you've encountered both names and are confused — that's normal. Here's the explanation.

Mounjaro:

• FDA approved in May 2022
• Official indication: type 2 diabetes
• Available in 6 dosages: 2.5, 5, 7.5, 10, 12.5, and 15 mg
• Form: KwikPen — pre-filled injection pen [4]

Zepbound:

• FDA approved in November 2023
• Official indication: chronic weight management in adults with obesity or overweight
• Same tirzepatide molecule

In Ukraine, Mounjaro is currently available — the original product manufactured by Eli Lilly, Made in UK. Despite the "diabetic" indication, DOZA specialists use it for weight correction programs with individual dose selection.

More about real weight loss program results can be read in our clients' reviews.

SURPASS: direct comparison with semaglutide

The SURPASS study series focused on tirzepatide's efficacy in type 2 diabetes. This is where the first direct comparison of the two molecules occurred.

SURPASS-2: tirzepatide versus semaglutide

This 40-week open-label study compared tirzepatide (5, 10, and 15 mg) with semaglutide 1 mg in patients with type 2 diabetes already taking metformin [1].

Tirzepatide wasn't just "non-inferior" — it showed statistically significant superiority in both key endpoints [1].

SURPASS-CVOT: heart safety

The SURPASS-CVOT study included 13,299 patients with type 2 diabetes and established atherosclerotic cardiovascular disease [1].

Key results:

• Tirzepatide showed non-inferior safety compared to dulaglutide regarding cardiovascular events
• Reduced overall mortality was recorded
• Slower decline in glomerular filtration rate (kidney protection)

More details about research and scientific base can be found on a separate page.

Tirzepatide vs semaglutide: what to choose?

Both molecules are effective. Both work. But there is a difference — and it's significant.

In the comparative study, average weight loss was 22.9 kg with tirzepatide versus 15 kg with semaglutide — a difference of almost 8 kilograms [5].

However, it's important to understand: tirzepatide may be associated with more gastrointestinal side effects at higher doses [5]. That's why individual dose selection is crucial.

Cardiovascular safety was confirmed in the SURPASS-CVOT study on over 13,000 patients [1]. Read more about side effects in the complete Mounjaro side effects guide.

How to get Mounjaro in Ukraine?

Tirzepatide under the brand Mounjaro is available in Ukraine through the DOZA online service.

What's included in the program:

• Original Mounjaro Made in UK
• Individual dose selection from 2.5 to 15 mg
• Specialist consultations throughout the program
• Support and answers to questions via Telegram
• Test dose option for new clients

The program starts with a free consultation where a specialist will assess your situation, answer questions, and suggest an optimal plan.

Where to order Mounjaro in Ukraine

Ready to start the course? Buy Mounjaro in Ukraine is available in the DOZA catalog — all 6 doses (2.5, 5, 7.5, 10, 12.5, 15 mg) with official thermal delivery within 24 hours and 24/7 specialist support. Current Mounjaro prices 2026 — from 1,000 ₴ for a test dose or 8,000 ₴/month for a complete program with monitoring.

Where to order DOZA products

DOZA supplies all products mentioned in the article with official cold chain and 24/7 specialist support. Choose what you need:

• Buy Ozempic in Ukraine — original semaglutide from Novo Nordisk with thermal delivery. Current Ozempic prices 2026 — from 1,600 ₴ for a starting dose.